Boston Scientific Corporation $BSX Shares Bought by Longbow Finance SA

Longbow Finance SA lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 96.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 121,861 shares of the medical equipment provider’s stock after acquiring an additional 59,829 shares during the period. Boston Scientific comprises approximately 1.2% of Longbow Finance SA’s holdings, making the stock its 24th largest holding. Longbow Finance SA’s holdings in Boston Scientific were worth $11,897,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BSX. Metis Global Partners LLC increased its stake in Boston Scientific by 0.7% during the third quarter. Metis Global Partners LLC now owns 66,394 shares of the medical equipment provider’s stock valued at $6,482,000 after purchasing an additional 478 shares during the last quarter. Public Sector Pension Investment Board boosted its holdings in shares of Boston Scientific by 98.2% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,823,481 shares of the medical equipment provider’s stock valued at $178,026,000 after buying an additional 903,448 shares during the period. Atria Investments Inc grew its position in shares of Boston Scientific by 85.8% during the 3rd quarter. Atria Investments Inc now owns 77,476 shares of the medical equipment provider’s stock valued at $7,564,000 after buying an additional 35,788 shares during the last quarter. Wedbush Securities Inc. grew its position in shares of Boston Scientific by 7.7% during the 3rd quarter. Wedbush Securities Inc. now owns 3,260 shares of the medical equipment provider’s stock valued at $318,000 after buying an additional 232 shares during the last quarter. Finally, Varma Mutual Pension Insurance Co raised its stake in Boston Scientific by 1.0% during the third quarter. Varma Mutual Pension Insurance Co now owns 270,881 shares of the medical equipment provider’s stock worth $26,446,000 after acquiring an additional 2,700 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. JPMorgan Chase & Co. cut their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Stifel Nicolaus lowered their price target on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Finally, Robert W. Baird cut their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.43.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $74.09 on Friday. The stock has a market cap of $109.83 billion, a P/E ratio of 38.19, a P/E/G ratio of 1.02 and a beta of 0.67. The firm’s 50-day simple moving average is $91.39 and its 200 day simple moving average is $97.90. Boston Scientific Corporation has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the company earned $0.70 EPS. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.